Literature DB >> 12768116

Ringer's ethyl pyruvate solution: a novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis.

Mitchell P Fink1.   

Abstract

Reactive species of oxygen have been implicated as being important mediators in a variety of pathologic conditions, including burns, various forms of ischemia/reperfusion injury, and hemorrhagic shock. Pyruvate, an intermediate in the metabolism of glucose, is a potent reactive species of oxygen scavenger. Pyruvate, however, is unstable in aqueous solutions, and has not been developed as a therapeutic agent. Ethyl pyruvate, a simple derivative of the parent compound, is thought to be more stable in solution. Ringer's ethyl pyruvate solution (REPS) has been evaluated in a number of preclinical studies using animal models of mesenteric ischemia/reperfusion injury, hemorrhagic shock, and acute endotoxemia. Treatment with REPS, when compared with treatment with Ringer's lactate solution, has been shown to be able to improve survival and decrease expression of proinflammatory mediators. REPS warrants further evaluation for the resuscitation of patients with hemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768116     DOI: 10.1097/01.TA.0000064522.75563.00

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  11 in total

1.  Direct energy delivery improves tissue perfusion after resuscitated shock.

Authors:  El Rasheid Zakaria; William D Ehringer; Nina Tsakadze; Na Li; R Neal Garrison
Journal:  Surgery       Date:  2005-08       Impact factor: 3.982

Review 2.  The ebb and flow of fluid (as in resuscitation).

Authors:  K L Mattox
Journal:  Eur J Trauma Emerg Surg       Date:  2014-08-20       Impact factor: 3.693

3.  Ringer's ethyl pyruvate solution attenuates hypoperfusion and renal injury after multivisceral ischemia-reperfusion in rabbits.

Authors:  Takashige Yamada; Daisuke Nishimura; Kei Inoue; Jungo Kato; Hiroshi Morisaki; Yoshifumi Kotake
Journal:  J Anesth       Date:  2020-01-09       Impact factor: 2.078

4.  Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Authors:  Alexander J Muller; James B DuHadaway; Daniel Jaller; Peter Curtis; Richard Metz; George C Prendergast
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

5.  Ethyl pyruvate inhibits hypoxic pulmonary vasoconstriction and attenuates pulmonary artery cytokine expression.

Authors:  Ben M Tsai; Tim Lahm; Eric D Morrell; Paul R Crisostomo; Jeffrey Poynter; Meijing Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

6.  Effects of ethyl pyruvate on myocardial apoptosis and expression of Bcl-2 and Bax proteins after ischemia-reperfusion in rats.

Authors:  Jialong Guo; Kailun Zhang; Yanmei Ji; Xionggang Jiang; Shunqing Zuo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

7.  Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats.

Authors:  Lu-Wen Wang; Li-Kun Wang; Hui Chen; Cheng Fan; Xun Li; Can-Ming He; Zuo-Jiong Gong
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 8.  Experimental treatments for mitochondrial dysfunction in sepsis: A narrative review.

Authors:  Guilang Zheng; Juanjuan Lyu; Jingda Huang; Dan Xiang; Meiyan Xie; Qiyi Zeng
Journal:  J Res Med Sci       Date:  2015-02       Impact factor: 1.852

Review 9.  Sepsis: from bench to bedside.

Authors:  Eliézer Silva; Rogério Da Hora Passos; Maurício Beller Ferri; Luiz Francisco Poli de Figueiredo
Journal:  Clinics (Sao Paulo)       Date:  2008-02       Impact factor: 2.365

10.  Up-regulated HMGB1 in EAM directly led to collagen deposition by a PKCβ/Erk1/2-dependent pathway: cardiac fibroblast/myofibroblast might be another source of HMGB1.

Authors:  Zhaoliang Su; Jingping Yin; Ting Wang; Yingkun Sun; Ping Ni; Rui Ma; Haitao Zhu; Dong Zheng; Huiling Shen; Wenlin Xu; Huaxi Xu
Journal:  J Cell Mol Med       Date:  2014-06-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.